Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
SINGAPORE, July 21, 2025 ( GLOBE NEWSWIRE ) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited ( NASDAQ: GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary ...
How this was made
The 30-second read
Why it matters
Milestone completion reduces clinical development risk, likely boosting investor confidence and stock price.
Market read
The news is relevant primarily to biotech investors and traders focusing on clinical trial developments.
What to watch
Potential delays in subsequent trial phases or regulatory hurdles could negate positive sentiment.
Background
CytoMed is advancing its ANGELICA trial for cancer therapeutics, with recent milestone achievement indicating progress.
Ticker impact
Primary focus due to recent clinical trial milestone; moderate impact on stock valuation.
Moderate upward movement expected in the short to medium term.
Successful trial progression is a key milestone that can positively influence stock valuation, especially given the company's focus on innovative therapeutics. The news reduces clinical development risk, which is generally viewed favorably by investors.
Market effects
Potential positive influence on biotech and pharmaceutical sectors, especially those involved in clinical trials.
Limited to Singapore and global biotech markets; no significant regional effects.
Moderate, as clinical trial milestones can affect global biotech investor sentiment.
Counterpoint
Some investors may view clinical trial progress as already priced in, leading to limited upside.
Key entities
- CompanyCytoMed Therapeutics Limited
A Singapore-based biopharmaceutical company focused on cancer therapeutics.





